USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/27061
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCroitoru, Dan-
dc.contributor.authorCorobcean, Nadejda-
dc.contributor.authorVișnevschi, Sergiu-
dc.date.accessioned2024-04-29T11:34:03Z-
dc.date.available2024-04-29T11:34:03Z-
dc.date.issued2024-
dc.identifier.citationCROITORU, Dan, COROBCEAN, Nadejda, VIȘNEVSCHI, Sergiu. Treatment in breast cancer using the CRISPR/Cas9 system. In: Cells and Tissues Transplantation. Actualities and Perspectives: the materials of the nat. scientific conf. with internat. particip., the 2nd ed. Chisinau, March 29-30th 2024: [abstracts]. Chişinău: CEP Medicina, 2024, p. 50. ISBN 978-9975-82-366-1.en_US
dc.identifier.isbn978-9975-82-366-1-
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/27061-
dc.description.abstractBackground. Breast cancer is the leading cause of death in the oncological population of female gender and the second most prevalent cause of overall death in the United States of America and the third most prevalent cancer death in Europe. There is a trend for breast cancer in caucasian, hispanic and asian women. Numerous methods of treatment are accepted – chemotherapy, molecular targeted therapy, radiotherapy, immunotherapy, phototherapy and surgical interventions (lumpectomy, mastectomy). The genome editing methods – clustered regularly interspaced short palindromic repeats (CRISPR) technology is developed based on the protection systems found in bacteria, the one which is useful in treating cancer is the Cas9 protein thus defining the CRISPR-Cas9 system. It’s main components are crRNA and tancrRNA (sgRNA) with the Cas protein. Material and methods. We used the PubMed database in order the collect the information. After introducting the key-words „CRISPR-Cas9” and „breast cancer” we revealed up to 571 sources. We have reviewed the first 100 sources and have studied 18 of them. One source was added non- sistematically. Overall we have reviewed 19 sources. Results. The CRISPR-Cas9 system can be delivered to the target cells via protein, lipid, polymer and inorganic based nanocarriers. Other method of delivery is via the lentiviral/adenoviral vectors. The most efficient ones are the gold nanocarriers (inorganic). The genome editing technology is based on plasmid systems that act via interference and activation thus making them useful for identifying biomarkers and in the diagnosis of breast cancer.The main genes that are targeted by the CRISPR-Cas9 system in breast cancer are BRCA1, BRCA2, MYC, CDK9, UBR5, ZNF319 kinome (HER2, PI3KCA and FGFR), CXCR4+CXCR7 (CXCL) and other tumour supressor genes (p53, PTEN, RB1 and NF1). The genes involved in metabolic pathways are upregulated in a secondary manner because of alterations in canceromatous states. Carcinogenesis, metastasis and resistance to drugs and radiotherapy is reduced after using this treatment method. Conclusions. CRISPR-Cas9 system is efficient in breast cancer treatment and diagnosis. It has perspectives in order to be used as an adjuvant method in this condition without regard to it’s high costs.en_US
dc.language.isoenen_US
dc.publisherCEP Medicinaen_US
dc.relation.ispartofCells and tissues transplantation. Actualities and perspectives. The 2-nd edition. Chisinau, March 29-30th 2024en_US
dc.subjectCRISPR-Cas9en_US
dc.subjectbreast canceren_US
dc.subjectdrug resistanceen_US
dc.subjectradioresistanceen_US
dc.titleTreatment in breast cancer using the CRISPR/Cas9 systemen_US
dc.typeOtheren_US
Appears in Collections:The Materials of the National Scientific Conference with International Participation, the 2nd edition, Chisinau, March 29-30th 2024: [Abstracts]

Files in This Item:
File Description SizeFormat 
TREATMENT_IN_BREAST_CANCER_USING_THE_CRISPRCAS9_SYSTEM.pdf301.93 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback